Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells  by Hong, Yuzhi et al.
Kidney International, Vol. 62 (2002), pp. 1291–1300
Triptolide is a potent suppressant of C3, CD40 and B7h
expression in activated human proximal tubular epithelial cells
YUZHI HONG,1 WUDING ZHOU,1 KE LI, and STEVEN H. SACKS
Department of Nephrology and Transplantation, Guy’s Hospital, London, England, United Kingdom
Triptolide is a potent suppressant of C3, CD40 and B7h expres- ment of autoimmune diseases such as rheumatoid arth-
sion in activated human proximal tubular epithelial cells. ritis, immune complex nephritis and systemic lupus
Background. Previous studies have shown that triptolide erythematosus (SLE) for many years [1–3]. In organpossesses potent immunosuppressive and anti-inflammatory
transplantation, both clinical and experimental studiesproperties. Increasing recognition of the importance of the
have demonstrated that Tripterygium extracts effectivelyproximal tubular epithelial cells (PTEC) in renal disease and
renal transplantation raises the question of whether triptolide prolong allograft survival [4–5]. However, the mecha-
suppresses the pro-inflammatory activity of PTEC. nism of its immunosuppressive action has not been
Methods. Cultured human PTEC were exposed to tumor completely delineated. The identification of triptolide, anecrosis factor- (TNF-) and immunosuppressant (triptolide
diterpene triepoxide, as an active component of Triptery-or CsA or FK506) for 24 hours, followed by RT-PCR, ELISA,
gium extracts has allowed study of the mechanism offlow cytometry and Western blotting analysis for complement
C3, CD40, B7h expression. this very effective traditional Chinese medicine. Recent
Results. TNF- up-regulated C3, CD40 and B7h production investigations have demonstrated that triptolide pos-
by PTEC. This up-regulation was inhibited by all three immu-
sesses immunosuppressive and anti-inflammatory prop-nosuppressants with different intensity. Firstly, triptolide (4 to
erties by preventing T cell proliferation, interferon-8 ng/mL), CsA (4000 to 6000 ng/mL) and FK506 (2000 ng/mL)
inhibited up-regulation of C3 mRNA, but CsA and FK506 had (IFN-) and interleukin-2 (IL-2) production [6, 7]. Over
less of an effect than triptolide. Secondly, triptolide (4 to 8 the past decade, proximal tubular epithelial cells (PTEC)
ng/mL) completely inhibited C3 expression at both mRNA have become an important focus for research into the
and protein levels. In contrast, CsA and FK506 had only slight
pathogenesis of renal disease and renal transplant injury.effects on C3 expression at the protein level. Thirdly, triptolide
Both in vitro and in vivo, studies have demonstrated(4 to 8 ng/mL), CsA (500 to 2500 ng/mL) and FK506 (1250
ng/mL) inhibited up-regulation of CD40 and B7h mRNA, the that the PTEC represent a prominent source for the
effect on B7h and CD40 mRNA expression by CsA and FK506 production of inflammatory mediators and may partici-
being greater than that on C3 mRNA expression. pate in the pathogenesis of tubulointerstitial injuryConclusion. Triptolide effectively inhibited up-regulation of
[8–10]. This raises the question of whether triptolide hasC3, CD40 and B7h on PTEC. Triptolide was more effective
a direct anti-inflammatory action on PTEC.than CsA and FK506 at inhibiting C3 expression. This suggests
that triptolide, at non-cytotoxic concentrations, has the poten- The complement system is an important mediator of
tial to reduce the inflammatory and immunostimulatory prop- inflammation, contributing to tissue injury in a number
erties of PTEC, in addition to any of the previously reported of conditions including renal transplant rejection [11].actions on T cell or B cell function.
The third component, C3, plays a pivotal role in comple-
ment activation and triggers the inflammatory response
through the release of anaphylatoxins and the formationExtracts of the plant Tripterygium Tilfordii Hook F.
of membrane attack complex [12]. Although the main(TWHF) possess potent immunosuppressive properties
source of production of C3 is the hepatocyte [13], it isthat have been used extensively in China for the treat-
now recognized that other cell types including PTEC
are a significant source of local, extrahepatic synthesis
1Drs. Hong and Zhou are equal contributors to this work. [10, 14]. In inflammatory conditions, PTEC expression
of C3 is increased [15, 16], such that during transplantKey words: immunosuppression, anti-inflammatory drug, renal trans-
plantation, PTEC pro-inflammation, cyclosporine A, FK506. rejection the inflamed kidney may contribute as much
as 15% of the circulating C3 [17]. Recently, it has beenReceived for publication December 14, 2001
shown that C3d, a breakdown product of C3, acts as anand in revised form April 11, 2002
Accepted for publication May 24, 2002 immunological adjuvant, reducing the threshold of the
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of magnitude [18]. Together, this evidence suggests that tration of immunosuppressants (triptolide, CsA or FK506)
local synthesis of C3 may not only participate in tissue for 24 hours. Cell viability (measured by exclusion of
inflammation, but also could act as a bridge between trypan blue) was 95 to 98% after treatment with the
innate immunity and the adaptive arm of the immune drug concentrations used in the inhibition studies and
response. in untreated cell cultures. For analysis of C3, B7h, CD40
Activation of lymphocytes in the development of mRNA, total RNA was extracted from cells cultured in
adaptive immunity requires two distinct signals. The first the flasks as described below. For detection of C3 pro-
one, resulting from the engagement of the TCR:CD3 tein, the supernatant in each well of six-well plates was
complex by major histocompatibility complex (MHC) harvested for C3 enzyme-linked immunosorbent assay
molecules bearing the relevant antigenic peptide, is nec- (ELISA). For the cytotoxicity assay, cells were cultured
essary but not sufficient. The second, provided by co- in 24 well plates.
stimulatory molecules, such as B7 family members, CD40
Cytotoxicity assayand intercellular adhesion molecule (ICAM), play a vital
role in the immune response. The central role of these The assay was performed with a CytoTox 96 Non-
co-stimulatory pathways in allograft rejection was illus- radioactive Cytotoxicity Assay kit (Promega, Southamp-
trated by multiple rodent experiments [19]. It is now ton, UK), following the manufacturer’s instruction.
known that the PTEC is not only a major source of Briefly, after 24 hours incubation of cells with TNF-
biosynthesis of complement in injured kidney, but also and immunosuppressants, medium samples were col-
has the capacity to function as an antigen presenting cell lected and spun for five minutes at 4C, 13,000 rpm. To
(APC) owing to expression of MHC class II and of co- measure lactate dehydrogenase (LDH) activity, 50 L
stimulatory molecules such as CD40, CD40 ligand, and of each sample and 50 L of substrate were added in
a variety of adhesion molecules and cytokines [20–22]. each well of 96-well plate. The assay plate was incubated
In order to explore the immunosuppressive and anti- for 30 minutes at room temperature. The LDH activity
rejection properties of triptolide, we examined its effects was recorded after adding stop solution by measuring
on C3 and co-stimulatory molecule expression in cul- absorbance at 490 nm. Background values were derived
tured human PTEC stimulated by TNF-, and compared from the medium of untreated PTEC. Maximum LDH
the effectiveness of triptolide with the recognized immu- release values were derived from cell lysate by adding
nosuppressants such as cyclosporine A (CsA) and tacrol- cell lysis solution to the monolayer. The % cell death
imus (FK506). was determined using the formula:
% Cytotoxicity  Experimental LDH release (OD490)
METHODS  Background values (OD490)
Cell culture Maximum LDH release (OD490)
Human PTEC clone was a gift from Professor L.C  Background values (OD490)
Racusen (Baltimore, MD, USA). The production and
All LDH assays were performed in triplicate.characteristics of this clone have been described pre-
viously [23]. The cells were grown in Dulbecco’s modified
Reverse transcription of RNA and subsequent PCREagle’s medium (DMEM)/Ham’s F12 (1:1) containing
Total RNA was prepared from cultured PTEC as de-2% heat-inactivated fetal calf serum (FCS), insulin (5
scribed previously for reverse transcription-polymeraseg/mL), transferrin (5g/mL), selenium (5 ng/mL), pen-
chain reaction (RT-PCR) [24]. In brief, cells were lysedicillin (100 U/mL) and streptomycin (100 g/mL). All
in 4 mol/L guanidinium thiocyanate, 25 mmol/L sodiumcell culture reagents were purchased from Gibco BRL
citrate, pH 7.0, 0.5% sarcosyl, and 0.1 mol/L 2-mercapto-(Uxbridge, UK).
ethanol, and followed by phenol/chloroform:isoamyl al-
Cytokine stimulation and immunosuppressant cohol extraction and isopropanol precipitation. RNA
treatment of PTEC was quantified by absorbance at 260 nm. cDNA synthesis
was carried out with 5 g of total RNA, 160 ng of oli-Triptolide (molecular weight 360, purity 97%) was
go(dT)12-18, 500 mol/L of each dNTP, and 200 U Molo-purchased from the Medical Science Institute of China
ney murine leukemia virus (M-MLV) reverse tran-(Nanjing, China). It was dissolved in ethanol and further
scriptase in 20 L of solution [50 mmol/L Tris-HCl, pHdiluted to the indicated concentration with culture me-
8.3, 75 mmol/L KCl, 10 mmol/L dithiothreitol (DTT), 3dium. CsA (Sandoz Pharmaceutical, East Hanover, NJ,
mmol/L MgCl2, 1.5 U/mL Rnasin] at 37C for 45 minutes.USA) and FK506 (Fujisawa Pharmaceutical Co. Ltd,
At the end of the reaction, cDNA was further dilutedOsaka, Japan) were directly diluted in cell culture me-
with sterile water (30 L of water was added in 20 Ldium. The cells were incubated with or without TNF-
and in the absence or presence of the indicated concen- of reaction mixture) and stored at 20C until further
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Table 1. PCR primer sequences and product sizes
Primera Oligonucleotide sequence Product size bp Genbank code
C3-1 5-GCTGCTCCTGCTACTAACCCA-3 784 K02765
C3-2 5-AAAGGCAGTTCCCTCCACTTT-3
CD40-1 5-CCTCGCTATGGTTCGTCTGCC-3 740 AF199028
CD40-2 5-AGCCAGGAAGATCGTCGGGA-3
B7h-1 5-TTTACTGTCACGGTTCCCAAGG-3 645 XM_029940
B7h-2 5-CCTCTGGCACATCCTCCAAATG-3
GAPDH-1 5-ACCACAGTCCATGCCATCAC-3 453 XM_033260
GAPDH-2 5-TCCACCACCCTGTTGCTGTA-3
aPrimer-1 is identical to the coding strand; primer-2 is complementary to the coding strand
use. PCR was carried out with 2 L of the diluted cDNA, Western blotting
12.5 pmol each of 3 and 5 primers of C3, B7h and CD40 protein expressed by PTEC was examined by
CD40 (Table 1), 200 mol/L of each dNTP, 3 U of Western blotting. PTEC cultured in plates were lysed
Taq polymerase in 25 L of reaction buffer (Promega, with M-PER reagent (Perbio Science, Cheshire, UK).
Southampton, UK). The PCR cycle consisted of one The cell lysate was eletrophoresed under non-reducing
minute of denaturation at 94C, one minute of primer conditions and transferred to a Hybound enhanced
annealing at 65C, and one minute of extension/synthesis chemiluminescence (ECL) membrane (Amersham Phar-
at 72C. After 26 cycles of amplification, samples were macia, Biotech) using a semi-dry blotting unit (Hoefer
incubated for another ten minutes at 72C. Amplified Scientific Instrument, San Francisco, CA, USA). Mem-
PCR products were visualized after electrophoresis on brane was incubated with a blocking buffer (3% BSA
1.2% agarose gel containing ethidium bromide and quan- in PBS) at 4C overnight and then incubated with mouse
tified using Qgel 1-D software (Stratagene, Cambrige, monoclonal anti-human CD40 (Cymbus Biotech, Chan-
UK). For quantification, glyceraldehyde-3-phosphate dlers Ford, UK) diluted 1/100, followed by incubation
dehydrogenase (GAPDH) primers, 12.5 pmol each, also with peroxidase conjugated rabbit anti-mouse IgG di-
were added in every reaction as an internal control. The luted 1/3000. An identical membrane was incubated with
yield of products was expressed as a ratio to GAPDH.
rabbit anti-human decay acceleration factor (DAF; Sero-
All PCR studies were performed in duplicate.
tec, Oxford, UK) instead of anti-CD40 as a loading con-
trol. It is reported that human DAF expression is notSandwich ELISA for C3
regulated by various cytokines on renal epithelial cellsThe amount of C3 secreted in cell culture supernatant
[26]. A study in our lab also confirmed that DAF expres-was measured using a sandwich ELISA as described
sion on PTEC was not regulated by TNF- (unpublishedpreviously [25]. In brief, 96 well plate (Nunc, Roskilde,
data). Each antibody incubation was performed in PBSDenmark) was coated overnight at 4C with sheep anti-
containing 3% BSA, 0.1% Tween at room temperaturehuman C3c (the Binding Site, Birmingham, UK) diluted
for one hour and followed by washing in PBS with 0.2%1/200 in phosphate-buffered saline (PBS). After blocking
Tween for three times, each time for 15 minutes. Mem-with PBS containing 2% bovine serum albumin (BSA),
brane was then developed using an ECL reagent (Amer-the plate was incubated with appropriately diluted super-
sham Pharmacia, Biotech). Raji cells (a B cell line) werenatant samples, followed by rabbit anti-human C3c
used as positive control for CD40.(Dako, High Wycombe, UK) diluted 1/3000, then peroxi-
dase conjugated goat anti-rabbit IgG diluted 1/5000.
Flow cytometry
Each antibody incubation was performed in 100 L of
Cultured PTEC were incubated with 25 mmol/L ethyl-PBS containing 2% BSA, 0.1% Tween at 37C for one
enediaminetetraacetic acid (EDTA; pH 7.6) for five min-hour and followed by washing in PBS containing 0.05%
utes at 37C, detached cells were collected and washedTween for three times. The enzyme activity was read
in PBS. Five 	 105 cells were incubated with 2 g ofafter incubation with O-phenylenediamine by measuring
mouse monoclonal anti-human CD40 antibody, followedabsorbance at 490 nm. The OD reading for the medium
by incubation with goat anti-mouse IgG diluted 1/25containing 2% FCS was subtracted from that for each
(Sigma, Poole, UK) conjugated with fluorescein. Eachtest sample, before converting the OD reading to C3
antibody incubation was performed in 50 L of PBSconcentration. A pooled normal human serum of known
with 1% BSA at 4C for one hour, followed by washingC3 concentration was used to generate a standard curve
three times in 2 mL of PBS with 1% BSA. The cellsand was incubated in every reaction. The limit of sensitiv-
were then fixed in 400 L of 2% paraformaldehyde inity of this assay was 0.3 ng/mL. ELISA studies were
performed in triplicate. PBS and analyzed by flow cytometry (FACScan flow
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Fig. 1. Tumor necrosis factor- (TNF-) induced up-regulation of C3 production by proximal tubule epithelial cells (PTEC). PTEC were incubated
with TNF- at the indicated concentrations for 24 hours and followed by RT-PCR and ELISA. (A ) Upper panel, a typical agarose gel showing
the 784 bp PCR product of C3 and the 453 bp PCR product of GAPDH (internal control). Lane M, 100 bp DNA markers. Lower panel, bars
representing the C3/GAPDH ratio of PCR products scanned from the agarose gels and quantified using Qgel-1D software. C3 gene up-regulation
is seen with TNF- stimulation, in a dose dependent manner. (B ) C3 ELISA results showing C3 protein secretion is up-regulated by TNF-, in
a dose dependent manner. *P 
 0.05 and **P 
 0.01 compared with unstimulated cells.
cytometry; Becton Dickson, Mountain View, CA, USA). these doses were not cytotoxic in trypan blue studies and
an LDH releases assay (discussed later in this section) ofRaji cells were used as positive control for CD40.
cultured PTEC. To determine the effects of triptolide,
Statistical analysis CsA and FK506 on C3 mRNA expression, PTEC were
All PCR and ELISA data shown are representative incubated with or without TNF- (2.5 ng/mL) for 24
of four independent experiments. Statistical analysis was hours in the presence of triptolide or CsA or FK506 at
performed on complete data sets from two of these inde- various concentrations, and analyzed by RT-PCR. Trip-
tolide at doses of 4 and 8 ng/mL significantly inhibitedpendent experiment, with PCR products assayed in du-
C3 mRNA expression up-regulated by TNF- (Fig. 2A).plicate and ELISA in triplicate. Data were expressed as
Although CsA (4000 to 6000 ng/mL) and FK506 (2000mean  SEM and subjected to the Student t test.
ng/mL) exhibited an inhibitory effect on C3 mRNA ex-
pression, they had less of an effect than triptolide (Fig.RESULTS
2 B, C). The molar concentrations of triptolide, CsA and
TNF- up-regulates C3 production by PTEC FK506 used in this experiment were 0.01 to 0.02 mol/L,
Previous studies showed that PTEC were able to syn- 3.3 to 5.0 mol/L and 2.5 mol/L, respectively. There-
thesize C3, and such synthesis was up-regulated by a fore, on a molar as well as weight basis there were sig-
nificant differences in the effectiveness of these threevariety of cytokines. To demonstrate that TNF- can
drugs.up-regulate C3 gene expression by PTEC, RT-PCR was
performed. As shown in Figure 1A, C3 mRNA was de-
Inhibitory effects of triptolide, CsA and FK506 on C3tected in unstimulated PTEC, and after 24 hours stimula-
protein secretion by TNF- stimulated PTECtion with TNF-, C3 mRNA expression was increased
As shown in Figure 3, all three immunosuppressantsin a dose-dependent manner. PCR product was increased
were able to inhibit TNF- stimulated C3 protein synthe-about threefold in TNF- treated cells at dose of 2.5
sis by PTEC, but with very distinct differences of actionng/mL. To confirm that the C3 transcript expression led
intensity. Similar in effect on C3 mRNA expression, trip-to protein synthesis, secreted C3 was measured by
tolide at doses of 4 and 8 ng/mL inhibited TNF- up-ELISA. Corresponding to C3 mRNA expression, up-
regulated synthesis of C3 protein (Fig. 3A). The inhibi-regulation of the synthesis of C3 protein by TNF- also
tory effect of CsA and FK506 on C3 protein synthesisoccurred in a dose-dependent manner (Fig. 1B).
was much weaker than that of triptolide (Fig. 3 B, C).
Inhibitory effects of triptolide, CsA and FK506 on C3 FK506 at a dose of 2000 ng/mL (effective dose of inhibi-
mRNA expression by TNF- stimulated PTEC tion of C3 mRNA expression) had no effect on C3 pro-
tein secretion, although a small effect was observed afterWe selected the concentrations of drugs used in this
study based on previous studies [6, 27], and verified that increasing the dose of FK506 to 6000 ng/mL.
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Fig. 2. Effects of triptolide, cyclosporine A (CsA) and FK506 on C3 mRNA expression by tumor necrosis factor- (TNF-) stimulated proximal
tubule epithelial cells (PTEC). PTEC were incubated with TNF- 2.5 ng/mL and in the presence of triptolide or CsA or FK506 at the indicated
concentrations for 24 hours and followed by RT-PCR. In the upper panels A-C, the typical agarose gels showing the C3 and GAPDH PCR
products. Lane M, 100 bp DNA markers. Lower panels show bars representing the C3/GAPDH ratio of PCR products. (A ) Triptolide inhibited
C3 mRNA expression at dose 4 to 8 ng/mL. (B ) CsA inhibited C3 mRNA expression at dose 4000 and 6000 ng/mL. (C ) FK506 inhibited C3
mRNA expression at dose 2000 ng/mL. *P 
 0.05 and **P 
 0.01 compared with TNF- stimulated cells in the absence of immunosuppressant.
TNF- up-regulates CD40 expression by and 2500 ng/mL) and FK506 (1250 ng/mL) also effec-
tively inhibited CD40 mRNA expression in these cells.human PTEC
To demonstrate that TNF- can up-regulate CD40 Inhibitory effects of triptolide, CsA and FK506 on
expression by PTEC, we performed RT-PCR and West- CD40 protein production by TNF- stimulated PTEC
ern blotting. When PTEC were incubated with TNF-
Proximal tubule epithelial cells were incubated with2.5 ng/mL for 24 hours, CD40 mRNA expression and
or without TNF- (2.5 ng/mL) in the presence of triptol-
protein synthesis were increased by three- and sixfold,
ide (8 ng/mL), CsA (2500 ng/mL) or FK506 (1250 ng/mL)
respectively (Fig. 4). for 24 hours and followed by flow cytometry analysis. As
shown in Figure 6, the three immunosuppressants at theInhibitory effects of triptolide, CsA and FK506 CD40
doses shown to inhibit CD40 mRNA expression alsomRNA expression by TNF- stimulated PTEC
were able to reduce CD40 protein expression on TNF-
To examine the effects of these three immunosuppres- stimulated cells.
sants on CD40 mRNA expression by TNF-–stimulated
TNF- up-regulates B7h expression by human PTECPTEC, the cells were incubated with or without TNF-
(2.5 ng/mL) in the presence of triptolide, CsA or FK506 A previous study has showed that B7h mRNA was
for 24 hours and followed by RT-PCR. As shown in detected in kidney tissue [28], however, the cells produc-
Figure 5, triptolide (4 and 8 ng/mL) inhibited CD40 ing this molecule are unknown. We therefore performed
RT-PCR to examine if PTEC is able to express B7h,mRNA expression by stimulated cells. Both CsA (500
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Fig. 3. Effects of triptolide, CsA and FK506 on C3 protein production by TNF- stimulated PTEC. PTEC were incubated with TNF- 2.5 ng/mL
and in the presence of triptolide or CsA or FK506 for 24 hours and followed by ELISA. (A ) Triptolide inhibited C3 protein secretion at doses
of 4 and 8 ng/mL. (B ) Inhibitory doses of CsA were 4000 and 6000 ng/mL. (C ) Significant FK506 inhibition of C3 protein secretion was not
observed even with at dose 6000 ng/mL. *P 
 0.05 and **P 
 0.01 compared with TNF- stimulated cells but in the absence of immunosuppressant.
Fig. 4. TNF- up-regulation of CD40 production by PTEC. PTEC were incubated without or with TNF- 2.5 ng/mL for 24 hours and followed
by RT-PCR and western blotting. (A ) Upper panel, a typical agarose gel showing the 740 bp CD40 band and the 453 bp GAPDH (internal
control) band. Lane M, 100 bp DNA markers. Lower panel, bars representing the CD40/GAPDH ratio of PCR products. (B ) Upper panel, protein
blots showing the 48 kD CD40 band and the 70 kD DAF (loading control) band. Lower panel, bars representing the CD40/DAF ratio of protein
blots scanned and quantified using Qgel-1D software. TNF- up-regulated CD40 mRNA expression and protein synthesis significantly. **P 

0.01 compared with unstimulated cells.
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Fig. 6. Effects of triptolide, CsA and FK506 on C40 protein expression
by TNF- stimulated PTEC. PTEC were incubated with TNF- 2.5
ng/mL and in the presence of triptolide (8 ng/mL) or CsA (2500
ng/mL) or FK506 (1250 ng/mL) for 24 hours and followed by flow
cytometry analysis. Results were expressed as the intensity of the me-
dian fluorescence of each test sample minus that of isotype control
antibody staining. *P 
 0.05 and **P 
 0.01 compared with TNF-
stimulated cells but in the absence of immunosuppressant.
Fig. 5. Effects of triptolide, CsA and FK506 on CD40 mRNA expres-
sion by TNF- stimulated PTEC. PTEC were incubated with TNF-
2.5 ng/mL and in the presence of triptolide or CsA or FK506 for 24
hours and followed by RT-PCR. Bars represent the CD40/GAPDH
ratio of PCR products. (A ) Triptolide inhibited CD40 mRNA expres- Fig. 7. TNF- up-regulation of B7h mRNA expression by PTEC.
sion at 2 to 8 ng/mL. (B ) CsA inhibited CD40 mRNA expression at PTEC were incubated without or with TNF- 2.5 ng/mL for 24 hours
100-2500 ng/mL. (C ) FK506 inhibited CD40 mRNA expression at 250 and followed by RT-PCR. Upper panel, a typical agarose gel showing
to 1250 ng/mL. *P 
 0.05 compared with TNF- stimulated cells but the 645 bp B7h band and the 453 bp GAPDH (internal control) band.
in the absence of immunosuppressant. Lane M, 100 bp DNA markers. Lower panel, bars representing the
CD40/GAPDH ratio of PCR products. TNF- significantly up-regulated
B7h mRNA expression. **P 
 0.01 compared with un-stimulated cells.
and whether B7h expression is up-regulated by TNF-.
A 654 bp of B7h PCR product was detected in both
TNF- stimulated and unstimulated PTEC, and TNF-
stimulation increased B7h mRNA expression by 2.5-fold and FK506 (50 to 1250 ng/mL) inhibited B7h mRNA
(Fig. 7). expression up-regulated by TNF-.
Inhibitory effects of triptolide, CsA and FK506 on Suppressive effect on PTEC is not related to drug
B7h mRNA expression by TNF- stimulated PTEC induced cytotoxicity
To examine the effects of these three immunosuppres- To ensure that triptolide, CsA and FK506 were non-
sants on B7h mRNA expression in TNF- stimulated cytotoxic at the concentrations used in our study, LDH
PTEC, the cells were incubated with or without TNF- release from target cells (cultured PTEC) was measured
(2.5 ng/mL) in the presence of triptolide or CsA or FK506 after treatment with TNF- and immunosuppressants.
for 24 hours and followed by RT-PCR. As shown in Triptolide (2 to 8 ng/mL), CsA (100 to 3000 ng/mL) and
FK506 (50 to 1350 ng/mL) produced 0% cytotoxicity.Figure 8, triptolide (8 ng/mL), CsA (500 and 2500 ng/mL)
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pene tripoxide, is the major active component that ac-
counts for the potent immunosuppressive effects of
TWHF [29]. Because of its beneficial clinical impact,
including anti-rejection properties, efforts have been
made to understand the mechanisms by which these
preparations exert their immunosuppressive effects. Pre-
vious studies have demonstrated that the active compo-
nents of extract of TWHF are capable of inhibiting sev-
eral immune functions, including the response of human
peripheral blood mononuclear cells to either mitogen
or alloantigen and the generation of cytotoxic T cells
[30], T cell proliferation and production of IFN- [7]
and early cytokines (such as IL-2) transcribed during
T cell activation [6, 31]. Our study showed that tripto-
lide, through inhibiting C3, B7h and CD40 production,
strongly suppresses the pro-inflammatory and immuno-
regulatory properties of tubular epithelial cells at rela-
tively low concentrations. The beneficial effect of triptol-
ide on organ transplant survival, therefore, could partly
reflect an action on graft cells, rendering them less capa-
ble of stimulating an inflammatory response.
It has been shown that cultured human PTEC exposed
to IL-2 and IFN- increase the secretion of C3 [14].
Our current study demonstrates that TNF- also can up-
regulate C3 mRNA expression and C3 protein secretion
by cultured human PTEC, in both a dose and time (data
not shown) dependent manner.
Importantly, our study found that triptolide effectively
inhibits TNF- up-regulated C3 mRNA and protein ex-
pression at a concentration of 4 to 8 ng/mL. In contrast,
CsA and FK506 had only slight effects even at concentra-
tions of 4000 ng/mL and 2000 ng/mL, respectively, which
is far beyond the therapeutic blood concentration of 200
Fig. 8. Effects of triptolide, CsA and FK506 on B7h mRNA expression to 250 ng/mL for CsA and 5 to 16 ng/mL for FK506.
by TNF- stimulated PTEC. PTEC were incubated with TNF- 2.5 Therapeutic concentrations of CsA or FK506 had no
ng/mL and in the presence of triptolide or CsA or FK506 for 24 hours
effect on C3 (data not shown), but nevertheless possessand followed by RT-PCR. Bars represent the B7h/GAPDH ratio of
PCR products. (A ) Triptolide inhibited B7h mRNA expression at dose strong inhibition of T cell activation [32]. Furthermore,
2 to 8 ng/mL. (B ) CsA inhibited B7h mRNA expression at dose 500 at the high levels of calcineurin inhibitors used, FK506
and 2500 ng/mL. (C ) FK506 inhibited B7h mRNA expression at dose
appeared to be twice as potent as CsA on C3 mRNA50-1250 ng/mL. *P 
 0.05 and **P 
 0.01 compared with TNF-
stimulated cells but in the absence of immunosuppressant. expression, yet had a weaker effect on C3 protein synthe-
sis. This apparent difference in the mechanism of inhib-
iting C3 expression could be explained if the main effect
of FK506 were at the level of C3 gene transcription, and
if the main effect of CsA were a secondary effect uponHigher doses of triptolide (24 ng/mL), CsA (9000 ng/mL)
protein synthesis or secretion of C3.and FK506 (4050 ng/mL) gave 2.3, 5 and 2.4% cytotoxic-
Primary T cell activation requires B7-CD28 and CD40-ity, respectively. Therefore, at the concentrations used
CD40 ligand co-stimulation, while effector T cell func-in this study (Figs. 2, 3, 5, 6 and 8), triptolide, CsA and
tions are considered to be largely independent of theseFK506 had no cytotoxic effect on cultured PTEC. At
co-stimulatory pathways [33]. Recent studies have showndrug concentrations three- to fivefold above this range,
that ICOS-B7h co-stimulation may be required for thethere was minimal cytotoxicity.
development of acute and chronic rejection [34]. Induc-
ible co-stimulator (ICOS) is the third member of CD28
DISCUSSION family that is expressed preferentially by activated T
cells, and studies of ICOS/ mice show that ICOS co-At least 70 compounds have been isolated from
TWHF and structurally identified. Triptolide, a diter- stimulation is necessary for the activation and function
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of effector T cells [35, 36]. B7h was identified as a B7 and CD40 stimulated by TNF-, which acts as a pro-
homolog and also is termed as B7-related protein 1. inflammatory factor by inducing activation of NF-B.
B7h is abundantly expressed in heart, skeletal muscle, The absence of LDH release, demonstration of well
placenta, lung, and has lower expression in thymus, maintained cell viability and unaltered house keeping
spleen, liver and kidney [28]. Both ICOS and B7h are up- gene expression indicate that the reduced mRNA and
regulated during the development of allograft rejection protein expression reported here are unlikely to repre-
[34]. Our study identifies the PTEC as a possible site of sent toxicity of the reagents.
B7h up-regulation in renal tissue. Up-regulation of B7h Major advances in clinical transplantation have been
by TNF- may function to directly augment recognition made possible largely by the development of effective
of self during inflammation. In addition, as the expres- immunosuppressive agents such as CsA and FK506.
sion of this pathway is relevant to the pathogenesis of However, the limitations of CsA and FK506 are well
both acute and chronic rejection, regulation of this path- known, and significant drug-toxicity and acute rejection
way therefore might have therapeutic potential in trans- episodes are regularly observed with calcineurin inhibi-
plantation, as well as autoimmune disease. tor-based regimens [40, 41]. Therefore, immunosuppres-
Proximal tubule epithelial cells are thought to play a sive therapy for allograft rejection is still an important
critical role in the pathogenesis of renal injury, due to limitation in organ transplantation. New immunosup-
their ability to secrete proinflammatory and profibro- pressants are therefore currently being explored.
genic substances [9, 37–39]. In addition, because these Recently, a study indicated that triptolide and PG27,
cells reside at the interface between the urinary space, a refined Tripterygium extract that contains triptolide as
interstitium and peritubular capillaries, they are in a its active compound, significantly increases the median
unique position to sense changes in the composition of survival time of rat cardiac and renal allografts, with less
the glomerular filtrate and co-ordinate proinflammatory nephrotoxicity than CsA [4]. It also indicated that CsA
and immunoregulatory functions in the renal intersti- combined with triptolide shows a strongly synergistic
tium. There is growing evidence that the PTEC, in addi- effect, even at doses of CsA ineffective when adminis-
tion to responding to blood borne substances at their tered alone [4]. Further, in vitro evidence suggests that
basolateral surface, can be activated at their apical sur- immunosuppression with triptolide was greater than with
face by a number of substances abnormally present in CsA, especially for ongoing lymphoblast formation [42].
the urine, such as filtered proteins and inflammatory
It also has been reported that triptolide was more effec-
reactants [37–39]. PTEC also are able to express MHC
tive at inhibiting T cell proliferation and IFN- produc-class II and co-stimulatory molecules, enabling them to
tion than FK506 [7]. The contribution of our presentinteract with T cells [20–22]. Our experiments confirm
study is to strongly support the results of these studies,that PTEC monolayers, when stimulated by cytokines
namely that triptolide, at a concentration that appearssuch as TNF, applied to their apical surface, can react
to lack cytotoxicity in vitro, has the potential to lower thein a pro-inflammatory and immunomodulatory manner.
pro-inflammatory and immunostimulatory properties ofMoreover, the significant damping effect of triptolide on
graft itself, in addition to any direct immunoregulatoryB7h and CD40 expression as well as on C3 expression
effects on T cells or B cells. It may have value, for exam-suggests that triptolide could have an inhibitory effect
ple, in suppressing the inflammatory response to reperfu-on such PTEC functions. The effect of triptolide in sup-
sion injury, in addition to its central immunosuppressantpressing the inflammatory responses of PTEC may be
effects.as relevant to other forms of renal injury as well as
transplantation.
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